{"id":"imlifidase","rwe":[{"pmid":"41740237","year":"2026","title":"Molecular diagnostics in HLA-incompatible kidney transplantation.","finding":"","journal":"Transplantation reviews (Orlando, Fla.)","studyType":"Clinical Study"},{"pmid":"41737221","year":"2026","title":"Novel assays to assess the prevalence and neutralizing potential of anti-IdeS antibodies in healthy humans.","finding":"","journal":"Frontiers in immunology","studyType":"Clinical Study"},{"pmid":"41631379","year":"2026","title":"Managing the highly sensitized kidney transplant patient.","finding":"","journal":"Current opinion in organ transplantation","studyType":"Clinical Study"},{"pmid":"41578965","year":"2026","title":"Trends in Nephrology: From nihilism to targeted treatment of antibody-mediated rejection.","finding":"","journal":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","studyType":"Clinical Study"},{"pmid":"41522684","year":"2026","title":"Complement activation in anti-glomerular basement membrane disease before and after treatment with imlifidase.","finding":"","journal":"Clinical kidney journal","studyType":"Clinical Study"}],"tags":[{"label":"Biologic","category":"modality"},{"label":"Immunoglobulin gamma (IgG), heavy chain","category":"target"},{"label":"IGHG1","category":"gene"},{"label":"IGHG2","category":"gene"},{"label":"IGHG3","category":"gene"},{"label":"L04AA41","category":"atc"},{"label":"Active","category":"status"},{"label":"Renal transplant rejection","category":"indication"},{"label":"Transplant of kidney","category":"indication"},{"label":"Hansa Biopharma AB","category":"company"}],"phase":"marketed","safety":{"contraindications":["Thrombotic thrombocytopenic purpura"]},"trials":[],"aliases":[],"company":"Hansa Biopharma AB","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=IMLIFIDASE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:21:05.707830+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:21:11.574537+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T01:21:05.775819+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=IMLIFIDASE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:21:11.974215+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Antibodies hydrolytic enzyme","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:21:13.029561+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297981/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:21:12.684164+00:00"}},"allNames":"ides","offLabel":[],"synonyms":["imlifidase","idefirix","HMED-IdeS","IdeS"],"timeline":[{"date":"2020-08-26","type":"positive","source":"DrugCentral","milestone":"EMA approval (Hansa Biopharma AB)"}],"approvals":[{"date":"2020-08-26","orphan":true,"company":"Hansa Biopharma AB","regulator":"EMA"}],"brandName":"Ides","ecosystem":[{"indication":"Renal transplant rejection","otherDrugs":[{"name":"basiliximab","slug":"basiliximab","company":"Novartis"},{"name":"belatacept","slug":"belatacept","company":"Bristol Myers Squibb"},{"name":"daclizumab","slug":"daclizumab","company":"Hoffman-La Roche"},{"name":"muromonab-CD3","slug":"muromonab-cd3","company":"Ortho Biotech"}],"globalPrevalence":null},{"indication":"Transplant of kidney","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Immunoglobulin gamma (IgG), heavy chain","targets":[{"gene":"IGHG1","source":"DrugCentral","target":"Immunoglobulin gamma (IgG), heavy chain","protein":"Ig gamma-1 chain C region"},{"gene":"IGHG2","source":"DrugCentral","target":"Immunoglobulin gamma (IgG), heavy chain","protein":"Ig gamma-2 chain C region"},{"gene":"IGHG3","source":"DrugCentral","target":"Immunoglobulin gamma (IgG), heavy chain","protein":"Ig gamma-3 chain C region"},{"gene":"IGHG4","source":"DrugCentral","target":"Immunoglobulin gamma (IgG), heavy chain","protein":"Ig gamma-4 chain C region"}],"modality":"Biologic","explanation":"","oneSentence":"","technicalDetail":"Ides specifically targets the IgG heavy chain, a key component of IgG antibodies, through a small molecule modality, thereby facilitating the breakdown of these antibodies by the body's natural processes."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5418","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=IMLIFIDASE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=IMLIFIDASE","fields":["publications"],"source":"PubMed/NCBI"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T12:03:22.525578","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:21:14.338098+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"muromonab-CD3","drugSlug":"muromonab-cd3","fdaApproval":"1992-09-14","relationship":"same-class"},{"drugName":"mycophenolic acid","drugSlug":"mycophenolic-acid","fdaApproval":"2004-02-27","relationship":"same-class"},{"drugName":"sirolimus","drugSlug":"sirolimus","fdaApproval":"1999-09-15","patentExpiry":"Oct 28, 2040","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"leflunomide","drugSlug":"leflunomide","fdaApproval":"1998-09-10","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"alefacept","drugSlug":"alefacept","fdaApproval":"2003-01-30","relationship":"same-class"},{"drugName":"everolimus","drugSlug":"everolimus","fdaApproval":"2009-03-30","patentExpiry":"May 1, 2026","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"efalizumab","drugSlug":"efalizumab","fdaApproval":"2003-10-27","relationship":"same-class"},{"drugName":"natalizumab","drugSlug":"natalizumab","fdaApproval":"2004-11-23","relationship":"same-class"},{"drugName":"abatacept","drugSlug":"abatacept","fdaApproval":"2005-12-23","relationship":"same-class"},{"drugName":"eculizumab","drugSlug":"eculizumab","fdaApproval":"2007-03-16","relationship":"same-class"},{"drugName":"belimumab","drugSlug":"belimumab","fdaApproval":"2011-03-09","relationship":"same-class"},{"drugName":"fingolimod","drugSlug":"fingolimod","fdaApproval":"2010-09-21","patentExpiry":"Sep 30, 2032","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"belatacept","drugSlug":"belatacept","fdaApproval":"2011-06-15","relationship":"same-class"},{"drugName":"tofacitinib","drugSlug":"tofacitinib","fdaApproval":"2012-11-06","patentExpiry":"Sep 14, 2034","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"teriflunomide","drugSlug":"teriflunomide","fdaApproval":"2012-09-12","patentExpiry":"Sep 14, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"apremilast","drugSlug":"apremilast","fdaApproval":"2014-03-21","patentExpiry":"Nov 29, 2034","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"vedolizumab","drugSlug":"vedolizumab","fdaApproval":"2014-05-20","relationship":"same-class"},{"drugName":"alemtuzumab","drugSlug":"alemtuzumab","fdaApproval":"2001-05-07","relationship":"same-class"},{"drugName":"ocrelizumab","drugSlug":"ocrelizumab","fdaApproval":"2017-03-28","relationship":"same-class"},{"drugName":"baricitinib","drugSlug":"baricitinib","fdaApproval":"2018-05-31","patentExpiry":"Nov 30, 2032","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"imlifidase","indications":{"approved":[{"name":"Renal transplant rejection","source":"DrugCentral","snomedId":236570004,"regulator":"FDA"},{"name":"Transplant of kidney","source":"DrugCentral","snomedId":70536003,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"muromonab-cd3","brandName":"muromonab-CD3","genericName":"muromonab-CD3","approvalYear":"1992","relationship":"same-class"},{"drugId":"mycophenolic-acid","brandName":"mycophenolic acid","genericName":"mycophenolic acid","approvalYear":"2004","relationship":"same-class"},{"drugId":"sirolimus","brandName":"sirolimus","genericName":"sirolimus","approvalYear":"1999","relationship":"same-class"},{"drugId":"leflunomide","brandName":"leflunomide","genericName":"leflunomide","approvalYear":"1998","relationship":"same-class"},{"drugId":"alefacept","brandName":"alefacept","genericName":"alefacept","approvalYear":"2003","relationship":"same-class"},{"drugId":"everolimus","brandName":"everolimus","genericName":"everolimus","approvalYear":"2009","relationship":"same-class"},{"drugId":"efalizumab","brandName":"efalizumab","genericName":"efalizumab","approvalYear":"2003","relationship":"same-class"},{"drugId":"natalizumab","brandName":"natalizumab","genericName":"natalizumab","approvalYear":"2004","relationship":"same-class"},{"drugId":"abatacept","brandName":"abatacept","genericName":"abatacept","approvalYear":"2005","relationship":"same-class"},{"drugId":"eculizumab","brandName":"eculizumab","genericName":"eculizumab","approvalYear":"2007","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05679401","phase":"PHASE3","title":"A Study With Imlifidase in Anti-GBM Disease","status":"TERMINATED","sponsor":"Hansa Biopharma AB","startDate":"2022-12-22","conditions":["Anti-Glomerular Basement Membrane Disease","Anti-Glomerular Basement Membrane Antibody Disease","Goodpasture Syndrome","Good Pasture Syndrome"],"enrollment":50,"completionDate":"2026-02-02"},{"nctId":"NCT07379957","phase":"","title":"Imlifidase for Highly Sensitized Kidney Transplant Recipients With a posItive crossmAtch Against a Deceased Donor: Results of Kidney Transplantations Performed in Accordance to the French Guidelines.","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Bordeaux","startDate":"2026-01","conditions":["Kidney Transplantation"],"enrollment":450,"completionDate":"2029-02"},{"nctId":"NCT05937750","phase":"PHASE3","title":"A Long-term Follow-up Trial of Patients Previously Treated With Imlifidase Prior to Kidney Transplantation and a Non-comparative Transplanted Patient Group","status":"RECRUITING","sponsor":"Hansa Biopharma AB","startDate":"2023-07-03","conditions":["Long Term Efficacy and Safety"],"enrollment":150,"completionDate":"2030-04-30"},{"nctId":"NCT06241950","phase":"PHASE1","title":"A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74)","status":"TERMINATED","sponsor":"Sarepta Therapeutics, Inc.","startDate":"2024-01-29","conditions":["Duchenne Muscular Dystrophy"],"enrollment":5,"completionDate":"2025-10-10"},{"nctId":"NCT05714514","phase":"","title":"Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of Kidneys","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hansa Biopharma AB","startDate":"2023-04-21","conditions":["Kidney Transplantation in Highly Sensitized Patients"],"enrollment":64,"completionDate":"2029-12-31"},{"nctId":"NCT05049850","phase":"PHASE2","title":"A Study to Investigate DSA Rebound in Patients Treated With Imlifidase Prior to Transplantation","status":"TERMINATED","sponsor":"Hansa Biopharma AB","startDate":"2022-12-16","conditions":["Kidney Transplantation in Highly Sensitized Patients"],"enrollment":3,"completionDate":"2024-05-08"},{"nctId":"NCT04935177","phase":"PHASE3","title":"Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx","status":"COMPLETED","sponsor":"Hansa Biopharma AB","startDate":"2021-10-14","conditions":["Kidney Transplantation in Highly Sensitized Patients"],"enrollment":64,"completionDate":"2025-06-20"},{"nctId":"NCT04711850","phase":"","title":"An Long-term Follow-up Trial of Kidney Tx Patients Treated With Imlifidase or PE After an AMR","status":"TERMINATED","sponsor":"Hansa Biopharma AB","startDate":"2021-01-20","conditions":["Kidney Transplant Rejection"],"enrollment":18,"completionDate":"2023-03-30"},{"nctId":"NCT03943589","phase":"PHASE2","title":"A Study of Imlifidase in Patients With Guillain-Barré Syndrome","status":"COMPLETED","sponsor":"Hansa Biopharma AB","startDate":"2019-11-12","conditions":["Guillain-Barré Syndrome (GBS)"],"enrollment":30,"completionDate":"2024-02-27"},{"nctId":"NCT05369975","phase":"PHASE3","title":"Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference Cohorts","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hansa Biopharma AB","startDate":"2022-04-19","conditions":["Kidney Transplantation in Highly Sensitized Patients"],"enrollment":225,"completionDate":"2026-04"},{"nctId":"NCT06461546","phase":"PHASE2","title":"Imlifidase in Living Donor Renal Transplantation Highly Sensitized Recipients","status":"WITHDRAWN","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2024-10-22","conditions":["Kidney Transplant Candidates"],"enrollment":0,"completionDate":"2027-05"},{"nctId":"NCT03611621","phase":"","title":"A Follow up Study of Patients Treated With Imlifidase Prior to Kidney Transplantation","status":"COMPLETED","sponsor":"Hansa Biopharma AB","startDate":"2018-06-27","conditions":["Kidney Transplant Failure and Rejection"],"enrollment":31,"completionDate":"2023-02-14"},{"nctId":"NCT05753930","phase":"PHASE2","title":"Imlifidase Prior to Kidney Transplant in Highly Sensitised Children","status":"RECRUITING","sponsor":"Hansa Biopharma AB","startDate":"2023-06-02","conditions":["Kidney Transplantation in Highly Sensitized Patients"],"enrollment":10,"completionDate":"2031-08-31"},{"nctId":"NCT06518005","phase":"PHASE2","title":"Efficacy and Safety of GNT0003 Following Imlifidase Pre-treatment in Severe Crigler-Najjar Syndrome","status":"RECRUITING","sponsor":"Genethon","startDate":"2024-11-08","conditions":["Crigler-Najjar Syndrome"],"enrollment":3,"completionDate":"2030-09-30"},{"nctId":"NCT03897205","phase":"PHASE2","title":"An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients","status":"COMPLETED","sponsor":"Hansa Biopharma AB","startDate":"2019-04-30","conditions":["Kidney Transplant Rejection"],"enrollment":30,"completionDate":"2022-11-16"},{"nctId":"NCT02426684","phase":"PHASE1,PHASE2","title":"Ides in Highly Sensitized (HS) Patients Awaiting Kidney Transplantation","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2015-06-16","conditions":["Renal Disease"],"enrollment":17,"completionDate":"2017-11-10"},{"nctId":"NCT03157037","phase":"PHASE2","title":"Open-Label Phase II Study to Evaluate the Efficacy and Safety of IdeS in Anti-GBM Disease","status":"COMPLETED","sponsor":"Mårten Segelmark","startDate":"2017-06-16","conditions":["Anti-Glomerular Basement Membrane Antibody Disease"],"enrollment":15,"completionDate":"2020-07-24"},{"nctId":"NCT02854059","phase":"PHASE2","title":"IdeS in Asymptomatic Antibody-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Patients","status":"TERMINATED","sponsor":"Hansa Biopharma AB","startDate":"2016-09","conditions":["Purpura, Thrombotic Thrombocytopenic"],"enrollment":2,"completionDate":"2017-01"}],"_emaApprovals":[{"date":"2020-08-26","status":"Authorised","company":"Hansa Biopharma AB"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"018684","UNII":"UVJ7NL8S2P","INN_ID":"10617","UMLSCUI":"C5139878","chemblId":"CHEMBL4297981","ChEMBL_ID":"CHEMBL4297981","KEGG_DRUG":"D11470","DRUGBANK_ID":"DB15258"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Hansa Biopharma AB","relationship":"Original Developer"}],"publicationCount":91,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"L04AA41","allCodes":["L04AA41"]},"biosimilarFilings":[],"originalDeveloper":"Hansa Biopharma AB","recentPublications":[{"date":"2026 Apr","pmid":"41740237","title":"Molecular diagnostics in HLA-incompatible kidney transplantation.","journal":"Transplantation reviews (Orlando, Fla.)"},{"date":"2026","pmid":"41737221","title":"Novel assays to assess the prevalence and neutralizing potential of anti-IdeS antibodies in healthy humans.","journal":"Frontiers in immunology"},{"date":"2026 Apr 1","pmid":"41631379","title":"Managing the highly sensitized kidney transplant patient.","journal":"Current opinion in organ transplantation"},{"date":"2026 Jan 24","pmid":"41578965","title":"Trends in Nephrology: From nihilism to targeted treatment of antibody-mediated rejection.","journal":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association"},{"date":"2026 Jan","pmid":"41522684","title":"Complement activation in anti-glomerular basement membrane disease before and after treatment with imlifidase.","journal":"Clinical kidney journal"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Hansa Biopharma AB","companyId":"hansa-biopharma-ab","modality":"Enzyme","firstApprovalDate":"2020","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":7,"withResults":2},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:21:14.338098+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}